Skip to content
2000
image of Oral Microbiota Associated with Clinical Efficacy of Ustekinumab in Crohn’s Disease
file format pdf download PDF

Abstract

Background

Crohn’s Disease (CD) is a chronic inflammatory gastrointestinal disease. Ustekinumab (UST) has been utilized as a therapeutic option for CD patients. However, approximately 40-60% of patients exhibit an inadequate response to UST. Accumulating evidence has confirmed the involvement of oral bacteria in the development of CD. Nevertheless, the relationship between oral microbiota and the efficacy of UST therapy in CD patients has remained unexplored.

Materials and Methods

We recruited 28 healthy individuals and 53 CD patients, 47 of whom completed the entire UST therapy. Oral samples and clinical data were collected. The clinical response and clinical remission were defined based on the CDAI score. Oral samples were analyzed by 16S rRNA gene sequencing. The analysis of sequence data was performed by QIIME and R.

Results

We revealed the oral microbial difference between the Healthy Control (HC) group and the CD group. The enrichment of , , , and , and the diminution of and were observed in the CD group. Differences in oral microbiota were also identified among patients with different efficacy of UST. Compared to the response and remission groups, both the non-response and non-remission groups showed significantly higher levels of and . Predictive models for clinical response and clinical remission in UST were developed based on oral microbiota, with the Area Under the Curve (AUC) value of 0.944 and 0.930, respectively.

Conclusion

Oral microbiota was relevant to the UST efficacy in patients with CD based on the predictive model. These findings suggest that oral microbiota could serve as a non-invasive prognostic biomarker for UST treatment in CD patients.

© 2025 The Author(s). Published by Bentham Science Publisher.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303363951241209060903
2025-01-13
2025-10-31

  • From This Site

    /content/journals/emiddt/10.2174/0118715303363951241209060903
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/emiddt/10.2174/0118715303363951241209060903/BMS-EMIDDT-2024-395.html?itemId=/content/journals/emiddt/10.2174/0118715303363951241209060903&mimeType=html&fmt=ahah

References

  1. Torres J. Mehandru S. Colombel J.F. Peyrin-Biroulet L. Crohn’s disease. Lancet 2017 389 10080 1741 1755 10.1016/S0140‑6736(16)31711‑1 27914655
    [Google Scholar]
  2. Alatab S. Sepanlou S.G. Ikuta K. Vahedi H. Bisignano C. Safiri S. Sadeghi A. Nixon M.R. Abdoli A. Abolhassani H. Alipour V. Almadi M.A.H. Almasi-Hashiani A. Anushiravani A. Arabloo J. Atique S. Awasthi A. Badawi A. Baig A.A.A. Bhala N. Bijani A. Biondi A. Borzì A.M. Burke K.E. Carvalho F. Daryani A. Dubey M. Eftekhari A. Fernandes E. Fernandes J.C. Fischer F. Haj-Mirzaian A. Haj-Mirzaian A. Hasanzadeh A. Hashemian M. Hay S.I. Hoang C.L. Househ M. Ilesanmi O.S. Jafari Balalami N. James S.L. Kengne A.P. Malekzadeh M.M. Merat S. Meretoja T.J. Mestrovic T. Mirrakhimov E.M. Mirzaei H. Mohammad K.A. Mokdad A.H. Monasta L. Negoi I. Nguyen T.H. Nguyen C.T. Pourshams A. Poustchi H. Rabiee M. Rabiee N. Ramezanzadeh K. Rawaf D.L. Rawaf S. Rezaei N. Robinson S.R. Ronfani L. Saxena S. Sepehrimanesh M. Shaikh M.A. Sharafi Z. Sharif M. Siabani S. Sima A.R. Singh J.A. Soheili A. Sotoudehmanesh R. Suleria H.A.R. Tesfay B.E. Tran B. Tsoi D. Vacante M. Wondmieneh A.B. Zarghi A. Zhang Z-J. Dirac M. Malekzadeh R. Naghavi M. GBD 2017 Inflammatory Bowel Disease Collaborators The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 2020 5 1 17 30 10.1016/S2468‑1253(19)30333‑4 31648971
    [Google Scholar]
  3. Aniwan S. Park S.H. Loftus E.V. Epidemiology, natural history, and risk stratification of Crohn’s disease. Gastroenterol. Clin. North Am. 2017 46 3 463 480 10.1016/j.gtc.2017.05.003 28838409
    [Google Scholar]
  4. Gajendran M. Loganathan P. Catinella A.P. Hashash J.G. A comprehensive review and update on Crohn’s disease. Dis. Mon. 2018 64 2 20 57 10.1016/j.disamonth.2017.07.001 28826742
    [Google Scholar]
  5. Roda G. Chien Ng S. Kotze P.G. Argollo M. Panaccione R. Spinelli A. Kaser A. Peyrin-Biroulet L. Danese S. Crohn’s disease. Nat. Rev. Dis. Primers 2020 6 1 22 10.1038/s41572‑020‑0156‑2 32242028
    [Google Scholar]
  6. Sands B.E. Irving P.M. Hoops T. Izanec J.L. Gao L.L. Gasink C. Greenspan A. Allez M. Danese S. Hanauer S.B. Jairath V. Kuehbacher T. Lewis J.D. Loftus E.V. Jr Mihaly E. Panaccione R. Scherl E. Shchukina O.B. Sandborn W.J. Afzali A. Aitova L. Aldeguer i Mante X. Allez M. Altorjay I. Argüelles Arias F. Armuzzi A. Augustyn M. Bafutto M. Barrio J. Begun J. Behrend C. Bezemer G. Bonnaud G. Brankovic M. Byung I.J. Calvet Calvo X. Chachu K. Chebli J.M.F. Cheon J.H. Cichoz-Lach H. Clark L. Cummings F. Dalal K. Danese S. De Boer N. De Lourdes Ferrari M. Désilets E. Dugalic P. Duvall G. Fedorishina O. Filip R. Flores C. Fogel R. Fon J. Frankel M. Friedenberg K. Fries W. Galina V. Gietka P. Goel R. Hasselblatt P. Herfarth H. Herszényi L. Hindryckx P. Hoentjen F. Horjus Talabur Horje C. Iduru S. Irving P. Isfort R. Jairath V. Jones M. Kalimullina D. Katz J. Kaur M. Khurana S.K. Kim J.S. Kim Y. Kleczkowski D. Knezevic S. Knoll A. Korman L.Y. Kotzev I. Kulyapin A. Lee K.M. Leemreis D. Leszczyszyn J. Limdi J. Lissauer J. Loftus E. Malecka-Panas E. Marshall J. Mihály E. Milan L. Monteleone G. Nagorni A. Owczarek D. Palekar N. Panaccione R. Park Y.S. Park S.H. Parra R. Patai Á. Patel K. Patel B. Pershko A. Petrova E. Pineton de Chambrun G. Randall C. Riestra Menendez S. Ritter T. Rivero M. Roblin X. Rocca R. Romatowski J. Rydzewska G. Saibeni S. Salzberg B. Sarles H. Saunders J. Savarino E.V. Serclova Z. Shchukina O. Siegel J. Soofi N. Sparrow M. Stokesberry D. Suiter D. Svorcan P. Tkachev A. Tsonev N. Tünde K. Ulbrych J. Vanasek T. Varga M. Vermeire S. Vicente Lidon R. Weiss M.L. Wesley E. Winstead N. Wojcik K. Wypych J. Zaltman C. Zdena Z. SEAVUE Study Group Ustekinumab versus adalimumab for induction and maintenance therapy in biologic- naive patients with moderately to severely active Crohn’s disease: A multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet 2022 399 10342 2200 2211 10.1016/S0140‑6736(22)00688‑2 35691323
    [Google Scholar]
  7. Feagan B.G. Sandborn W.J. Gasink C. Jacobstein D. Lang Y. Friedman J.R. Blank M.A. Johanns J. Gao L.L. Miao Y. Adedokun O.J. Sands B.E. Hanauer S.B. Vermeire S. Targan S. Ghosh S. de Villiers W.J. Colombel J.F. Tulassay Z. Seidler U. Salzberg B.A. Desreumaux P. Lee S.D. Loftus E.V. Jr Dieleman L.A. Katz S. Rutgeerts P. UNITI–IM-UNITI Study Group Ustekinumab as induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med. 2016 375 20 1946 1960 10.1056/NEJMoa1602773 27959607
    [Google Scholar]
  8. Johnson A.M. Barsky M. Ahmed W. Zullow S. Galati J. Jairath V. Narula N. Peerani F. Click B.H. Coburn E.S. Dang T.T. Gold S. Agrawal M. Garg R. Aggarwal M. Mohammad D. Halloran B. Kochhar G.S. Todorowski H. Ud Din N.M. Izanec J. Teeple A. Gasink C. Muser E. Ding Z. Swaminath A. Lakhani K. Hogan D. Datta S. Ungaro R.C. Boland B.S. Bohm M. Fischer M. Sagi S. Afzali A. Ullman T. Lawlor G. Baumgart D.C. Chang S. Hudesman D. Lukin D. Scherl E.J. Colombel J.F. Sands B.E. Siegel C.A. Regueiro M. Sandborn W.J. Bruining D. Kane S. Loftus E.V. Jr Dulai P.S. The real-world effectiveness and safety of ustekinumab in the treatment of Crohn’s disease: Results from the success consortium. Am. J. Gastroenterol. 2023 118 2 317 328 10.14309/ajg.0000000000002047 36191274
    [Google Scholar]
  9. Gonczi L. Szanto K. Farkas K. Molnar T. Szamosi T. Schafer E. Golovics P.A. Barkai L. Lontai L. Lovasz B. Juhasz M. Patai A. Sarang K. Vincze A. Sarlos P. Farkas A. Dubravcsik Z. Toth T.G. Miheller P. Ilias A. Lakatos P.L. Clinical efficacy, drug sustainability and serum drug levels in Crohn’s disease patients treated with ustekinumab – A prospective, multicenter cohort from Hungary. Dig. Liver Dis. 2022 54 2 207 213 10.1016/j.dld.2021.07.008 34344576
    [Google Scholar]
  10. Dalal R.S. Njie C. Marcus J. Gupta S. Allegretti J.R. Predictors of ustekinumab failure in Crohn’s disease after dose intensification. Inflamm. Bowel Dis. 2021 27 8 1294 1301 10.1093/ibd/izaa282 33146703
    [Google Scholar]
  11. Barré A. Colombel J.F. Ungaro R. Review article: Predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2018 47 7 896 905 10.1111/apt.14550 29430672
    [Google Scholar]
  12. Roblin X. Duru G. Papamichael K. Cheifetz A.S. Kwiatek S. Berger A.E. Barrau M. Waeckel L. Nancey S. Paul S. Development of antibodies to ustekinumab is associated with loss of response in patients with inflammatory bowel disease. J. Clin. Med. 2023 12 10 3395 10.3390/jcm12103395 37240501
    [Google Scholar]
  13. Okuda H. Hosomi S. Itani S. Kurimoto N. Kobayashi Y. Nakata R. Nishida Y. Ominami M. Nadatani Y. Fukunaga S. Otani K. Kamata N. Tanaka F. Nagami Y. Taira K. Ohfuji S. Fujiwara Y. Pretreatment serum monocyte chemoattractant protein-1 as a predictor of long-term outcome by ustekinumab in patients with Crohn’s disease. J. Gastroenterol. Hepatol. 2023 38 6 910 920 10.1111/jgh.16151 36807301
    [Google Scholar]
  14. Gevers D. Kugathasan S. Denson L.A. Vázquez-Baeza Y. Van Treuren W. Ren B. Schwager E. Knights D. Song S.J. Yassour M. Morgan X.C. Kostic A.D. Luo C. González A. McDonald D. Haberman Y. Walters T. Baker S. Rosh J. Stephens M. Heyman M. Markowitz J. Baldassano R. Griffiths A. Sylvester F. Mack D. Kim S. Crandall W. Hyams J. Huttenhower C. Knight R. Xavier R.J. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 2014 15 3 382 392 10.1016/j.chom.2014.02.005 24629344
    [Google Scholar]
  15. Dinakaran V. Mandape S.N. Shuba K. Pratap S. Sakhare S.S. Tabatabai M.A. Smoot D.T. Farmer-Dixon C.M. Kesavalu L.N. Adunyah S.E. Southerland J.H. Gangula P.R. Identification of specific oral and gut pathogens in full thickness colon of colitis patients: Implications for colon motility. Front. Microbiol. 2019 9 3220 10.3389/fmicb.2018.03220 30666239
    [Google Scholar]
  16. Schmidt T.S.B. Hayward M.R. Coelho L.P. Li S.S. Costea P.I. Voigt A.Y. Wirbel J. Maistrenko O.M. Alves R.J.C. Bergsten E. de Beaufort C. Sobhani I. Heintz-Buschart A. Sunagawa S. Zeller G. Wilmes P. Bork P. Extensive transmission of microbes along the gastrointestinal tract. eLife 2019 8 e42693 10.7554/eLife.42693 30747106
    [Google Scholar]
  17. Flemer B. Warren R.D. Barrett M.P. Cisek K. Das A. Jeffery I.B. Hurley E. O’Riordain M. Shanahan F. O’Toole P.W. The oral microbiota in colorectal cancer is distinctive and predictive. Gut 2018 67 8 1454 1463 10.1136/gutjnl‑2017‑314814 28988196
    [Google Scholar]
  18. Xun Z. Zhang Q. Xu T. Chen N. Chen F. Dysbiosis and ecotypes of the salivary microbiome associated with inflammatory bowel diseases and the assistance in diagnosis of diseases using oral bacterial profiles. Front. Microbiol. 2018 9 1136 10.3389/fmicb.2018.01136 29899737
    [Google Scholar]
  19. Zhou T. Xu W. Wang Q. Jiang C. Li H. Chao Y. Sun Y. A L. The effect of the “Oral-Gut” axis on periodontitis in inflammatory bowel disease: A review of microbe and immune mechanism associations. Front. Cell. Infect. Microbiol. 2023 13 1132420 10.3389/fcimb.2023.1132420 36923589
    [Google Scholar]
  20. Abdelbary M.M.H. Hatting M. Bott A. Dahlhausen A. Keller D. Trautwein C. Conrads G. The oral-gut axis: Salivary and fecal microbiome dysbiosis in patients with inflammatory bowel disease. Front. Cell. Infect. Microbiol. 2022 12 1010853 10.3389/fcimb.2022.1010853 36275026
    [Google Scholar]
  21. Read E. Curtis M.A. Neves J.F. The role of oral bacteria in inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 2021 18 10 731 742 10.1038/s41575‑021‑00488‑4 34400822
    [Google Scholar]
  22. Park Y.E. Moon H.S. Yong D. Seo H. Yang J. Shin T.S. Kim Y.K. Kim J.R. Lee Y.N. Kim Y.H. Kim J.S. Cheon J.H. Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-α therapy in patients with inflammatory bowel diseases. Sci. Rep. 2022 12 1 6359 10.1038/s41598‑022‑10450‑2 35428806
    [Google Scholar]
  23. Quast C. Pruesse E. Yilmaz P. Gerken J. Schweer T. Yarza P. Peplies J. Glöckner F.O. The SILVA ribosomal RNA gene database project: Improved data processing and web-based tools. Nucleic Acids Res. 2013 41 Database issue D590 D596 23193283
    [Google Scholar]
  24. Bolyen E. Rideout J.R. Dillon M.R. Bokulich N.A. Abnet C.C. Al-Ghalith G.A. Alexander H. Alm E.J. Arumugam M. Asnicar F. Bai Y. Bisanz J.E. Bittinger K. Brejnrod A. Brislawn C.J. Brown C.T. Callahan B.J. Caraballo-Rodríguez A.M. Chase J. Cope E.K. Da Silva R. Diener C. Dorrestein P.C. Douglas G.M. Durall D.M. Duvallet C. Edwardson C.F. Ernst M. Estaki M. Fouquier J. Gauglitz J.M. Gibbons S.M. Gibson D.L. Gonzalez A. Gorlick K. Guo J. Hillmann B. Holmes S. Holste H. Huttenhower C. Huttley G.A. Janssen S. Jarmusch A.K. Jiang L. Kaehler B.D. Kang K.B. Keefe C.R. Keim P. Kelley S.T. Knights D. Koester I. Kosciolek T. Kreps J. Langille M.G.I. Lee J. Ley R. Liu Y.X. Loftfield E. Lozupone C. Maher M. Marotz C. Martin B.D. McDonald D. McIver L.J. Melnik A.V. Metcalf J.L. Morgan S.C. Morton J.T. Naimey A.T. Navas-Molina J.A. Nothias L.F. Orchanian S.B. Pearson T. Peoples S.L. Petras D. Preuss M.L. Pruesse E. Rasmussen L.B. Rivers A. Robeson M.S. II Rosenthal P. Segata N. Shaffer M. Shiffer A. Sinha R. Song S.J. Spear J.R. Swafford A.D. Thompson L.R. Torres P.J. Trinh P. Tripathi A. Turnbaugh P.J. Ul-Hasan S. van der Hooft J.J.J. Vargas F. Vázquez-Baeza Y. Vogtmann E. von Hippel M. Walters W. Wan Y. Wang M. Warren J. Weber K.C. Williamson C.H.D. Willis A.D. Xu Z.Z. Zaneveld J.R. Zhang Y. Zhu Q. Knight R. Caporaso J.G. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat. Biotechnol. 2019 37 8 852 857 10.1038/s41587‑019‑0209‑9 31341288
    [Google Scholar]
  25. Segata N. Izard J. Waldron L. Gevers D. Miropolsky L. Garrett W.S. Huttenhower C. Metagenomic biomarker discovery and explanation. Genome Biol. 2011 12 6 R60 10.1186/gb‑2011‑12‑6‑r60 21702898
    [Google Scholar]
  26. Langille M.G.I. Zaneveld J. Caporaso J.G. McDonald D. Knights D. Reyes J.A. Clemente J.C. Burkepile D.E. Vega Thurber R.L. Knight R. Beiko R.G. Huttenhower C. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat. Biotechnol. 2013 31 9 814 821 10.1038/nbt.2676 23975157
    [Google Scholar]
  27. Engevik M.A. Danhof H.A. Ruan W. Engevik A.C. Chang-Graham A.L. Engevik K.A. Shi Z. Zhao Y. Brand C.K. Krystofiak E.S. Venable S. Liu X. Hirschi K.D. Hyser J.M. Spinler J.K. Britton R.A. Versalovic J. Fusobacterium nucleatum secretes outer membrane vesicles and promotes intestinal inflammation. MBio 2021 12 2 e02706-20 10.1128/mBio.02706‑20 33653893
    [Google Scholar]
  28. Kitamoto S. Nagao-Kitamoto H. Jiao Y. Gillilland M.G. III Hayashi A. Imai J. Sugihara K. Miyoshi M. Brazil J.C. Kuffa P. Hill B.D. Rizvi S.M. Wen F. Bishu S. Inohara N. Eaton K.A. Nusrat A. Lei Y.L. Giannobile W.V. Kamada N. The intermucosal connection between the mouth and gut in commensal pathobiont-driven colitis. Cell 2020 182 2 447 462.e14 10.1016/j.cell.2020.05.048 32758418
    [Google Scholar]
  29. Rojas-Tapias D.F. Brown E.M. Temple E.R. Onyekaba M.A. Mohamed A.M.T. Duncan K. Schirmer M. Walker R.L. Mayassi T. Pierce K.A. Ávila-Pacheco J. Clish C.B. Vlamakis H. Xavier R.J. Inflammation-associated nitrate facilitates ectopic colonization of oral bacterium Veillonella parvula in the intestine. Nat. Microbiol. 2022 7 10 1673 1685 10.1038/s41564‑022‑01224‑7 36138166
    [Google Scholar]
  30. Kitamoto S. Kamada N. Periodontal connection with intestinal inflammation: Microbiological and immunological mechanisms. Periodontol. 2000 2022 89 1 142 153 10.1111/prd.12424 35244953
    [Google Scholar]
  31. Park S.Y. Hwang B.O. Lim M. Ok S.H. Lee S.K. Chun K.S. Park K.K. Hu Y. Chung W.Y. Song N.Y. Oral–gut microbiome axis in gastrointestinal disease and cancer. Cancers (Basel) 2021 13 9 2124 10.3390/cancers13092124 33924899
    [Google Scholar]
  32. Imai J. Ichikawa H. Kitamoto S. Golob J.L. Kaneko M. Nagata J. Takahashi M. Gillilland M.G. III Tanaka R. Nagao-Kitamoto H. Hayashi A. Sugihara K. Bishu S. Tsuda S. Ito H. Kojima S. Karakida K. Matsushima M. Suzuki T. Hozumi K. Watanabe N. Giannobile W.V. Shirai T. Suzuki H. Kamada N. A potential pathogenic association between periodontal disease and Crohn’s disease. JCI Insight 2021 6 23 e148543 10.1172/jci.insight.148543 34710061
    [Google Scholar]
  33. Lira-Junior R. Figueredo C.M. Periodontal and inflammatory bowel diseases: Is there evidence of complex pathogenic interactions? World J. Gastroenterol. 2016 22 35 7963 7972 10.3748/wjg.v22.i35.7963 27672291
    [Google Scholar]
  34. Atarashi K. Suda W. Luo C. Kawaguchi T. Motoo I. Narushima S. Kiguchi Y. Yasuma K. Watanabe E. Tanoue T. Thaiss C.A. Sato M. Toyooka K. Said H.S. Yamagami H. Rice S.A. Gevers D. Johnson R.C. Segre J.A. Chen K. Kolls J.K. Elinav E. Morita H. Xavier R.J. Hattori M. Honda K. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. Science 2017 358 6361 359 365 10.1126/science.aan4526 29051379
    [Google Scholar]
  35. Kitamoto S. Nagao-Kitamoto H. Hein R. Schmidt T.M. Kamada N. The bacterial connection between the oral cavity and the gut diseases. J. Dent. Res. 2020 99 9 1021 1029 10.1177/0022034520924633 32464078
    [Google Scholar]
  36. Lockhart P.B. Brennan M.T. Sasser H.C. Fox P.C. Paster B.J. Bahrani-Mougeot F.K. Bacteremia associated with toothbrushing and dental extraction. Circulation 2008 117 24 3118 3125 10.1161/CIRCULATIONAHA.107.758524 18541739
    [Google Scholar]
  37. Hajishengallis G. Interconnection of periodontal disease and comorbidities: Evidence, mechanisms, and implications. Periodontol. 2022 89 1 9 18 10.1111/prd.12430 35244969
    [Google Scholar]
  38. Schirmer M. Denson L. Vlamakis H. Franzosa E.A. Thomas S. Gotman N.M. Rufo P. Baker S.S. Sauer C. Markowitz J. Pfefferkorn M. Oliva-Hemker M. Rosh J. Otley A. Boyle B. Mack D. Baldassano R. Keljo D. LeLeiko N. Heyman M. Griffiths A. Patel A.S. Noe J. Kugathasan S. Walters T. Huttenhower C. Hyams J. Xavier R.J. Compositional and temporal changes in the gut microbiome of pediatric ulcerative colitis patients are linked to disease course. Cell Host Microbe 2018 24 4 600 610.e4 10.1016/j.chom.2018.09.009 30308161
    [Google Scholar]
  39. Machiels K. Pozuelo del Río M. Martinez-De la Torre A. Xie Z. Pascal Andreu V. Sabino J. Santiago A. Campos D. Wolthuis A. D’Hoore A. De Hertogh G. Ferrante M. Manichanh C. Vermeire S. Early postoperative endoscopic recurrence in Crohn’s disease is characterised by distinct microbiota recolonisation. J. Crohn’s Colitis 2020 14 11 1535 1546 10.1093/ecco‑jcc/jjaa081 32333762
    [Google Scholar]
  40. Kolenbrander P.E. Palmer R.J. Jr Periasamy S. Jakubovics N.S. Oral multispecies biofilm development and the key role of cell–cell distance. Nat. Rev. Microbiol. 2010 8 7 471 480 10.1038/nrmicro2381 20514044
    [Google Scholar]
  41. Warren R.L. Freeman D.J. Pleasance S. Watson P. Moore R.A. Cochrane K. Allen-Vercoe E. Holt R.A. Co-occurrence of anaerobic bacteria in colorectal carcinomas. Microbiome 2013 1 1 16 10.1186/2049‑2618‑1‑16 24450771
    [Google Scholar]
  42. Pascal V. Pozuelo M. Borruel N. Casellas F. Campos D. Santiago A. Martinez X. Varela E. Sarrabayrouse G. Machiels K. Vermeire S. Sokol H. Guarner F. Manichanh C. A microbial signature for Crohn’s disease. Gut 2017 66 5 813 822 10.1136/gutjnl‑2016‑313235 28179361
    [Google Scholar]
  43. Meng Q. Gao Q. Mehrazarin S. Tangwanichgapong K. Wang Y. Huang Y. Pan Y. Robinson S. Liu Z. Zangiabadi A. Lux R. Papapanou P.N. Guo X.E. Wang H. Berchowitz L.E. Han Y.W. Fusobacterium nucleatum secretes amyloid-like FadA to enhance pathogenicity. EMBO Rep. 2021 22 7 e52891 10.15252/embr.202152891 34184813
    [Google Scholar]
  44. Eribe E.R.K. Olsen I. Leptotrichia species in human infections II. J. Oral Microbiol. 2017 9 1 1368848 10.1080/20002297.2017.1368848 29081911
    [Google Scholar]
  45. Schrimsher J.M. McGuirk J.P. Hinthorn D.R. Leptotrichia trevisanii sepsis after bone marrow transplantation. Emerg. Infect. Dis. 2013 19 10 1690 1691 10.3201/eid1910.121048 24047561
    [Google Scholar]
  46. Eribe E.R.K. Olsen I. Leptotrichia species in human infections. Anaerobe 2008 14 3 131 137 10.1016/j.anaerobe.2008.04.004 18539056
    [Google Scholar]
  47. Kim C.H. Lee Y.U. Kim K.H. Kang S. Kang G.H. Chu H. Lee S. Comparison of metabolites and gut microbes between patients with ulcerative colitis and healthy individuals for an integrative medicine approach to ulcerative Colitis—A pilot observational clinical study (STROBE Compliant). Diagnostics (Basel) 2022 12 8 1969 10.3390/diagnostics12081969 36010319
    [Google Scholar]
  48. Ranganath N. Shirley J.D. Challener D.W. Stevens R.W. Kind D.R. Comba I.Y. Patel R. Schuetz A.N. Shah A.S. Leptotrichia bacteremia: 10-year retrospective clinical analysis and antimicrobial susceptibility profiles. J. Clin. Microbiol. 2023 61 2 e01733-22 10.1128/jcm.01733‑22 36715514
    [Google Scholar]
  49. Langfeldt D. Neulinger S.C. Stiesch M. Stumpp N. Bang C. Schmitz R.A. Eberhard J. Health- and disease-associated species clusters in complex natural biofilms determine the innate immune response in oral epithelial cells during biofilm maturation. FEMS Microbiol. Lett. 2014 360 2 137 143 10.1111/1574‑6968.12596 25212593
    [Google Scholar]
  50. Fan X. Alekseyenko A.V. Wu J. Peters B.A. Jacobs E.J. Gapstur S.M. Purdue M.P. Abnet C.C. Stolzenberg-Solomon R. Miller G. Ravel J. Hayes R.B. Ahn J. Human oral microbiome and prospective risk for pancreatic cancer: A population-based nested case-control study. Gut 2018 67 1 120 127 10.1136/gutjnl‑2016‑312580 27742762
    [Google Scholar]
/content/journals/emiddt/10.2174/0118715303363951241209060903
Loading
Oral Microbiota Associated with Clinical Efficacy of Ustekinumab in Crohn’s Disease
Bentham Science Publishers ; https://doi.org/10.2174/0118715303363951241209060903
/content/journals/emiddt/10.2174/0118715303363951241209060903
/content/journals/emiddt/10.2174/0118715303363951241209060903
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: Crohn's disease ; prognostic biomarker ; 16S rRNA ; ustekinumab ; oral microbiota ; non-invasive prognostic biomarker

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test